ReviewDrug development research2022
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Review in Drug development research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Transgenesis in Drug Discovery: Enhancing Target Identification and Validation.Molecular biotechnology · 2026Review
- The role of TLR4/NF-kB signaling axis in pneumonia: from molecular mechanisms to regulation by phytochemicals.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Caspase-independent cell death in lung cancer: from mechanisms to clinical applications.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Nanobodies: a new frontier in influenza virus neutralization.Folia microbiologica · 2025Review
- Feasible Preparation of Naphthalimide-Functionalized Zeolitic Imidazolate Framework-8 for Control, and Fluorescence Detection of Virus: Optimization of Model Study.Journal of fluorescence · 2025Article
- ADME analysis, metabolic prediction, and molecular docking of lipoic acid with SARS-CoV-2 Omicron spike protein.Scientific reports · 2025Article
- Article
- Predicting tuberculosis drug properties using extended energy based topological indices via a python driven QSPR approach.Scientific reports · 2025Article
- Fractional modeling and numerical investigations of COVID-19 epidemic model with non-singular fractional derivatives: a case study.Scientific reports · 2025Article
- Network Pharmacology and Experimental Validation Reveal Ganodermanontriol Modulates Pneumonia via TNF/NF-κB/MAPKs Signaling Pathway.Food science & nutrition · 2025Article
- Hypoxia signaling in cancer: HIF-1α stimulated by COVID-19 can lead to cancer progression and chemo-resistance in oral squamous cell carcinoma (OSCC).Discover oncology · 2025Review
- Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies.Medical oncology (Northwood, London, England) · 2025Review
- Deciphering Host-Virus Interactions and Advancing Therapeutics for Chronic Viral Infection.Viruses · 2025Review
- Harnessing the FOXO-SIRT1 axis: insights into cellular stress, metabolism, and aging.Biogerontology · 2025Review
- Hypoxia-inducible factor and cellular senescence in pulmonary aging and disease.Biogerontology · 2025Review
- On QSPR analysis of pulmonary cancer drugs using python-driven topological modeling.Scientific reports · 2025Article
- Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulations.Scientific reports · 2025Article
- Novel coumarin-based acetohydrazide-1,2,3-triazole derivatives as urease enzyme inhibitors: Synthesis,Heliyon · 2025Article
- Leveraging dynamics informed neural networks for predictive modeling of COVID-19 spread: a hybrid SEIRV-DNNs approach.Scientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The coronavirus disease-19 (COVID-19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.